Antiviral Treatment among Pregnant Women with Chronic Hepatitis B

Table 3

Proportion and types of antiviral agents received by women age 10–50 years with chronic hepatitis B virus infection.

	Total ()		Nonpregnant ()		Pregnant ()		Pregnant versus nonpregnant	Cost ($/day)
		%^†		%^†		%^†	value
Antiviral prescribed	1215	19.4	1151	20.0	64	12.6	<0.01
Antiviral							<0.01
Adefovir dipivoxil	102	8.4	99	8.6	3	4.7	0.357	32
Entecavir	483	39.8	475	41.3	8	12.5	<0.01	25
Lamivudine	73	6.0	59	5.1	14	21.9	<0.01	10
Telbivudine	20	1.6	18	1.6	2	3.1	0.284	22
Tenofovir    disoproxil fumarate	625	51.4	578	50.2	47	73.4	<0.01	25
Two or more drugs	88	7.2	78	6.8	10	15.6	0.020	—

Among 84 women coinfected with HIV and chronic hepatitis B virus infection, 5 (6.0%) were prescribed an antiviral, 2 (40%) adefovir dipivoxil, and 3 (60%) tenofovir disoproxil. None of the 5 coinfected women who received an antiviral was pregnant.
^†Percentages total more than 100% because some women received more than one antiviral.